Literature DB >> 31383678

High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.

Marie Lind-Holst1, Ulla Birgitte Hartling1, Anne Estmann Christensen1.   

Abstract

We report a 12-week-old boy presenting with incomplete refractory Kawasaki disease (KD) complicated with macrophage activation syndrome (MAS). The infant presented with cerebral irritability, pain, tachypnoea and vomiting for 10 days. He did not fulfil any of the classic diagnostic criteria for KD. Pericardial effusion on echocardiography in addition to severe dilatation of the coronary arteries in combination with leucocytosis and raised acute phase reactants led to the diagnosis of incomplete KD. Treatment with intravenous immunoglobulin and aspirin was initiated but without any response. The condition was subsequently refractory to additional treatment with infliximab and high-dose methylprednisolone. His condition worsened, fulfilling the criteria for MAS. High-dose anakinra was initiated, and remission of the inflammation was achieved. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  paediatrics (drugs and medicines); vasculitis

Mesh:

Substances:

Year:  2019        PMID: 31383678      PMCID: PMC6685371          DOI: 10.1136/bcr-2019-229708

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

Authors:  Paivi M Miettunen; Aru Narendran; Aarthi Jayanthan; Edward M Behrens; Randy Q Cron
Journal:  Rheumatology (Oxford)       Date:  2010-08-07       Impact factor: 7.580

2.  Hemophagocytic lymphohistiocytosis (HLH) and related disorders.

Authors:  Alexandra H Filipovich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

3.  Should refractory Kawasaki disease be considered occult macrophage activation syndrome?

Authors:  Ui-Yoon Choi; Seung-Beom Han; Soo-Young Lee; Dae-Chul Jeong
Journal:  Semin Arthritis Rheum       Date:  2016-08-17       Impact factor: 5.532

Review 4.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

5.  Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis.

Authors:  Bryce A Binstadt; Jami C Levine; Peter A Nigrovic; Kimberlee Gauvreau; Fatma Dedeoglu; Robert C Fuhlbrigge; Steven N Weindling; Jane W Newburger; Robert P Sundel
Journal:  Pediatrics       Date:  2005-06-01       Impact factor: 7.124

Review 6.  Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review.

Authors:  Sharath Kumar; Balu Vaidyanathan; S Gayathri; L Rajam
Journal:  Rheumatol Int       Date:  2010-12-05       Impact factor: 2.631

7.  Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.

Authors:  Francesca Minoia; Sergio Davì; AnnaCarin Horne; Erkan Demirkaya; Francesca Bovis; Caifeng Li; Kai Lehmberg; Sheila Weitzman; Antonella Insalaco; Carine Wouters; Susan Shenoi; Graciela Espada; Seza Ozen; Jordi Anton; Raju Khubchandani; Ricardo Russo; Priyankar Pal; Ozgur Kasapcopur; Paivi Miettunen; Despoina Maritsi; Rosa Merino; Bita Shakoory; Maria Alessio; Vyacheslav Chasnyk; Helga Sanner; Yi-Jin Gao; Zeng Huasong; Toshiyuki Kitoh; Tadej Avcin; Michel Fischbach; Michael Frosch; Alexei Grom; Adam Huber; Marija Jelusic; Sujata Sawhney; Yosef Uziel; Nicolino Ruperto; Alberto Martini; Randy Q Cron; Angelo Ravelli
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

8.  High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.

Authors:  Ashley Shafferman; James D Birmingham; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-11       Impact factor: 3.054

Review 9.  IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.

Authors:  Perrine Dusser; Isabelle Koné-Paut
Journal:  Front Pharmacol       Date:  2017-03-28       Impact factor: 5.810

10.  A child with resistant Kawasaki disease successfully treated with anakinra: a case report.

Authors:  J Sánchez-Manubens; A Gelman; N Franch; S Teodoro; J R Palacios; N Rudi; J Rivera; J Antón
Journal:  BMC Pediatr       Date:  2017-04-08       Impact factor: 2.125

View more
  12 in total

Review 1.  NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.

Authors:  Debashis Dutta; Jianuo Liu; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

2.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2021-02-15       Impact factor: 10.995

Review 3.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

4.  A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.

Authors:  Priya R Soni; Magali Noval Rivas; Moshe Arditi
Journal:  Curr Rheumatol Rep       Date:  2020-02-05       Impact factor: 4.686

5.  The CoV-2 outbreak: how hematologists could help to fight Covid-19.

Authors:  Sara Galimberti; Chiara Baldini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesco Ferro; Gabriele Buda; Edoardo Benedetti; Rita Fazzi; Laura Baglietto; Ersilia Lucenteforte; Antonello Di Paolo; Mario Petrini
Journal:  Pharmacol Res       Date:  2020-05-06       Impact factor: 7.658

6.  Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.

Authors:  Sofia Ajeganova; Ann De Becker; Rik Schots
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-11-24       Impact factor: 5.346

7.  Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports.

Authors:  Maria Vincenza Mastrolia; Giulia Abbati; Claudia Signorino; Ilaria Maccora; Edoardo Marrani; Ilaria Pagnini; Gabriele Simonini
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

8.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2020-10-03       Impact factor: 15.483

Review 9.  Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.

Authors:  Giovanna Ferrara; Teresa Giani; Maria Costanza Caparello; Carla Farella; Lisa Gamalero; Rolando Cimaz
Journal:  Paediatr Drugs       Date:  2020-12       Impact factor: 3.022

Review 10.  The off-label use of anakinra in pediatric systemic autoinflammatory diseases.

Authors:  Valerio Maniscalco; Sarah Abu-Rumeileh; Maria Vincenza Mastrolia; Edoardo Marrani; Ilaria Maccora; Ilaria Pagnini; Gabriele Simonini
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-16       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.